Main Menu Jump to Content Search
News & Resources

Olshan Represents Pharmacyclics in Successful $207.2 Million Public Offering

March 8, 2013

Olshan represented Pharmacyclics Inc., a NASDAQ-listed clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases, in a $207.2 million overnight public offering of 2.2 million shares of its common stock. Adam Finerman and Erik Syvertsen comprise the Olshan team that represented Pharmacyclics in this matter.

Back to Page